#Switzerland #Zug #Lumendi AG #DiLumen #MICRO-TECH

Lumendi AG Implements Strategic Restructuring

Lumendi AG, a prominent player in advanced endoluminal technologies, has successfully completed a strategic restructuring process that aims to stimulate growth, innovation, and market expansion. This significant transition took effect on May 1, 2025, allowing Lumendi AG to absorb the operational functions of Lumendi Ltd. and Lumendi International Ltd. In this new structure, Lumendi LLC, located in the U.S., will operate as a fully owned subsidiary of Lumendi AG, focusing on development, manufacturing, and marketing activities within the United States.

This change brings about a streamlined corporate framework, enhancing Lumendi's capacity to broaden its global presence, foster product innovation, and create new industry partnerships. The restructuring not only optimizes operations but also offers strategic flexibility that will support their endeavors in collaborations, financing, and efforts to penetrate new markets.

As part of this growth initiative, Lumendi LLC has expanded its U.S. commercial team. Key leadership and clinical support positions have been filled to bolster the sales and support structure. This development aligns with their vision to meet the rising demand for their cutting-edge platform technologies, notably the DiLumen® Endoluminal Interventional Platform (EIP), which includes the recently launched DiLumen EZ1 and DiLumen C1/Grasper.

Peter Johann, Ph.D., Chairman of Lumendi AG, expressed that this restructuring is a crucial move to position the company for upcoming growth phases. He noted, “It enhances our capability to introduce innovative, minimally invasive endoscopic devices to the market while providing us with the flexibility needed to build industry partnerships that will ultimately increase our sales. We are committed to offering healthcare professionals the most advanced endoluminal solutions.”

In addition to the restructuring, Lumendi AG has announced a new distribution partnership with MICRO-TECH Endoscopy for the United Kingdom and Ireland. MICRO-TECH is a well-established provider of endoscopic solutions and aligns with Lumendi’s growth ambitions. This partnership is expected to enhance Lumendi's access and support in these key European markets, promoting wider adoption of its endoluminal platforms.

About Lumendi

Lumendi AG, headquartered in Zug, Switzerland, is focused on developing innovative endoscopic devices that aim to improve patient outcomes and lower healthcare costs. Its wholly owned subsidiary, Lumendi LLC, is based in Westport, Connecticut, and plays a crucial role in the U.S. market, driving local manufacturing and commercial activities. For more insights about their offerings, visit www.lumendi.com or www.lumendilearning.com.